Xencor/$XNCR
1D1W1MYTD1Y5YMAX
Capital at risk
About Xencor
Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs.
- Ticker
- $XNCR
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 260
- Headquarters
- Pasadena, United States
- Website
- www.xencor.com
Xencor Metrics
BasicAdvanced
$1.8B
-
-$2.18
0.84
-
Price and volume
Market cap
$1.8B
Beta
0.84
52-week high
$30.61
52-week low
$8.29
Average daily volume
1.3M
Financial strength
Current ratio
6.391
Quick ratio
6.092
Long term debt to equity
0.276
Total debt to equity
0.338
Interest coverage (TTM)
-4.91%
Profitability
EBITDA (TTM)
-205.904
Gross margin (TTM)
-143.65%
Net profit margin (TTM)
-155.59%
Operating margin (TTM)
-205.84%
Effective tax rate (TTM)
-1.54%
Revenue per employee (TTM)
$400,000
Management effectiveness
Return on assets (TTM)
-16.83%
Return on equity (TTM)
-29.07%
Valuation
Price to revenue (TTM)
17.533
Price to book
3.62
Price to tangible book (TTM)
3.67
Price to free cash flow (TTM)
-8.836
Free cash flow yield (TTM)
-11.32%
Free cash flow per share (TTM)
-2.776
Growth
Revenue change (TTM)
-28.56%
Earnings per share change (TTM)
-9.27%
3-year revenue growth (CAGR)
-2.54%
10-year revenue growth (CAGR)
0.64%
3-year earnings per share growth (CAGR)
0.58%
10-year earnings per share growth (CAGR)
8.75%
What the Analysts think about Xencor
Analyst ratings (Buy, Hold, Sell) for Xencor stock.
Analyst projections of the future price of Xencor stock.
Bulls say / Bears say
XmAb819 is approaching an important value inflection, with Phase 1 expansion-cohort results scheduled for an oral ESMO 2026 presentation and a registration-enabling pivotal study planned for 2027 in advanced clear-cell renal cell carcinoma. (Xencor)
XmAb942’s Phase 1 results showed a projected 74.1-day terminal half-life, supportive tolerability and the potential for once-every-12-weeks maintenance dosing; its global Phase 2b ulcerative-colitis trial remains on track for a blinded interim analysis around year-end 2026. (Xencor)
The Alexion settlement delivers $105 million in two payments, while Xencor expects sufficient cash resources to fund operations and research programs through 2028; the company also received a $10 million Zenas regulatory milestone in June 2026. (Xencor)
Alexion’s $105 million settlement provides near-term cash, but it ends Xencor’s U.S. Ultomiris royalty stream; only ex-U.S. royalties remain, reducing a previously expected source of recurring revenue. (Xencor)
Genentech elected to terminate its collaboration agreement, effective September 4, 2026, and the sole active collaboration product had already been removed from Roche’s development pipeline, eliminating a source of partnered-program optionality. (SEC filing)
The wholly owned pipeline remains clinically early: XmAb412 only entered first-in-human testing in the third quarter of 2026, while plamotamab and XmAb657 remain in Phase 1 and XmAb819’s pivotal study is only planned for 2027. This leaves substantial clinical, regulatory and execution risk before potential product revenues. (Xencor)
Data summarised monthly by Lightyear AI. Last updated on 9 Sept 2026.
Xencor Financial Performance
Revenues and expenses
Xencor Earnings Performance
Company profitability
Upcoming events
No upcoming events
Xencor News
AllArticlesVideos
Funds containing Xencor
AllUSDGBPEUR
Fund name | Fund size | $XNCR weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.11% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.11% |
iShares S&P SmallCap 600$IDP6 | $3.2B | 0.08% |
iShares S&P Small Cap 600£ISP6 | £2.4B | 0.08% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.06% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.